Navigation Links
French Physicians to Conduct 2000-Patient Study of CATANIA(TM) Coronary Stent

NEWNAN, Ga., Oct. 30 /PRNewswire/ -- Physicians at more than 40 centers in France have joined a study of the CATANIA(TM) Coronary Stent with NanoThin Polyzene®-F manufactured by CeloNova BioSciences. With Professor Emmanuel Teiger and Doctor Paul Barragan as co-Principal Investigators, the researchers today announced the Assessment of The Latest Non-Thrombogenic Angioplasty (ATLANTA-France) stent study. Each center will enroll 50 patients with the first procedures expected in early November.

(Photo: )

(Photo: )

The study will evaluate the short-, mid- and long-term safety and efficacy of the CATANIA(TM) coronary stent for the treatment of up to three de novo native coronary artery lesions in a real word setting. "Professor Teiger and Doctor Barragan are independent and respected interventional cardiologists and we look forward to the results of their study," said Thomas A. Gordy, President and Chief Executive Officer of CeloNova BioSciences. "Physicians throughout France have already used the CATANIA(TM) stent, but this registry will increase participation over broad spectrum of new facilities to this stent without drugs on the surface and for which patient do not have to take long-term dual antiplatelet therapy."

The CATANIA(TM) stent is CE Marked and available throughout the European Union, in the Middle East, and Northern Africa. The stent, treated with CeloNova's anti-thrombotic and bacterial resistant Polyzene®-F surface is available in 60 sizes.

About CeloNova BioSciences: Headquartered in Newnan, Georgia, CeloNova develops novel medical devices that are enhanced by one of the Company's proprietary materials, Polyzene®-F, a lubricious, anti-thrombotic, anti-inflammatory, and bacterial-resistant surface treatment. The Company's current products include Embozene(TM) Color-Advanced Microspheres and the CATANIA(TM) Coronary Stent System with NanoThin Polyzene®-F. Both products are CE Marked. Embozene(TM) Microspheres have been approved by the FDA for the treatment of hypervascular tumors and arteriovenous malformations. For more information, please visit

    CONTACT:  Teresa Wilson
              CeloNova BioSciences, Inc.
              +1 (678) 895-6486
              +1 (770) 502-0304

SOURCE CeloNova BioSciences, Inc.

SOURCE CeloNova BioSciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. ScienceDirect to Host French-Language Journals from Elsevier Masson
2. Exiqon Appoints Cynthia French as Chief Scientific Officer and Erik Holmlin as Chief Commercial Officer
3. French Agency AMP Appoints Dr Kamel Senouci as Director of SIVAC Initiative (Supporting Independent Immunization and Vaccine Advisory Committees)
4. Pharmaxis Appoints French Distributor for Aridol(TM)
5. Diageo Sponsors Medical Society of the State of New Yorks Physicians Training Program
6. Young Physicians Demanding Advanced Laparoscopic Energy Instruments
7. FDA Approves Additional Dosage Strengths of Shires ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients
8. Physicians Practice, Loma Linda Partner to Improve Patient Care in Southern California
9. Physicians Reference Laboratory Announces New Diagnostic for Womens Health
10. Center for Molecular Medicine Partners with AviaraDx to Offer New Cancer Tests to Aid Physicians in Personalizing Treatment
11. Apieron, Inc. Announces FDA Clearance of the Insight(TM) eNO System to Assist Physicians with Patient Asthma Management
Post Your Comments:
(Date:11/30/2015)... , ... November 30, 2015 , ... ... a new, Good Manufacturing Practice (GMP) 10000 in the Santiago Marriott. The Global ... and is operated by a world-class team of qualified medical researchers and practitioners, ...
(Date:11/30/2015)... N.Y. , Nov. 30, 2015  Culprits ... by assistant chemistry professor Jan Halámek, is taking ...   --> ...   --> ... at UAlbany have discovered a straightforward concept for ...
(Date:11/30/2015)... HACKENSACK, N.J. , Nov. 30, 2015  Champions ... technology solutions and services to personalize the development and ... Ackerman , Chief Executive Officer, will be presenting at ... 2015 at 4:30pm Pacific Standard Time (PST).  The conference, ... Los Angeles, CA , will feature ...
(Date:11/30/2015)... , Nov. 30, 2015  AbbVie, is introducing ... focuses on a daily routine for managing the life-long ... medication can affect the way the body absorbs it ... their a daily routine are important. The goal of ... patients better manage their hypothyroidism by establishing a daily ...
Breaking Biology Technology:
(Date:11/26/2015)... DUBLIN , Nov. 26, 2015 Research ... of the "Capacitive Fingerprint Sensors - Technology and ... --> --> ... market, especially in smartphones. The fingerprint sensor vendor Idex ... fingerprint sensor units in mobile devices and of the ...
(Date:11/18/2015)... , Nov. 18, 2015  As new scientific ... children, doctors and other healthcare providers face challenges in ... families and patients. In addition, as more children continue ... a patient,s adulthood and old age. John ... The Children,s Hospital of Philadelphia (CHOP) . ...
(Date:11/17/2015)... 2015  Vigilant Solutions announces today that Mr. ... Directors. --> --> ... the partnership at TPG Capital, one of the largest ... Billion in revenue.  He founded and led TPG,s Operating ... companies, from 1997 to 2013.  In his first role, ...
Breaking Biology News(10 mins):